This work is licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
H. Sung, J. Ferlay, R. L. Siegel, M. Laversanne, I. Soerjomataram, A. Jemal and F. Bray, Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries, CA Cancer J. Clin.71(3) (2021) 209–249; https://doi.org/10.3322/caac.21660Search in Google Scholar
European Cancer Information System, Estimates of cancer incidence and mortality in 2020; https://ecis.jrc.ec.europa.eu/; last access date May 15, 2023.Search in Google Scholar
V. Foulon, P. Schöffski and P. Wolter, Patient adherence to oral anticancer drugs: An emerging issue in modern oncology, Acta Clin. Belg.66(2) (2011) 85–96; https://doi.org/10.2143/ACB.66.2.2062525Search in Google Scholar
F. Cardoso, S. Kyriakides, S. Ohno, F. Penault-Llorca, P. Poortmans, I. T. Rubio, S. Zackrisson and E. Senkus, Early breast cancer: ESMO clinical practice guidelines for diagnosis, treatment and follow-up, Ann. Oncol.30(10) (2019) 1194–1220; https://doi.org/10.1093/annonc/mdz173Search in Google Scholar
B. Makubate, P. T. Donnan, J. A. Dewar, A. M. Thompson and C. McCowan, Cohort study of adherence to adjuvant endocrine therapy, breast cancer recurrence and mortality, Br. J. Cancer108(7) (2013) 1515–1524; https://doi.org/10.1038/bjc.2013.116Search in Google Scholar
L. Li, B. Chang, X. Jiang, X. Fan, Y. Li, T. Li, S. Wu, J. Zhang, S. Kariminia and Q. Li, Clinical outcomes comparison of 10 years versus 5 years of adjuvant endocrine therapy in patients with early breast cancer, BMC Cancer18(1) (2018) Article ID 977 (11 pages); https://doi.org/10.1186/s12885-018-4878-4Search in Google Scholar
D. L. Hershman, T. Shao, L. H. Kushi, D. Buono, W. Y. Tsai, L. Fehrenbacher, M. Kwan, S. L. Gomez and A. I. Neugut, Early discontinuation and non-adherence to adjuvant hormonal therapy are associated with increased mortality in women with breast cancer, Breast Cancer Res. Treat.126(2) (2011) 529–537; https://doi.org/10.1007/s10549-010-1132-4Search in Google Scholar
T. L. Lash, M. P. Fox, J. L. Westrup, A. K. Fink and R. A. Silliman, Adherence to tamoxifen over the five-year course, Breast Cancer Res. Treat. 99(2) (2006) 215–220; https://doi.org/10.1007/s10549-006-9193-0Search in Google Scholar
J. Y. Lee and Y. H. Min, Relationships between determinants of adjuvant endocrine therapy adherence in breast cancer, BMC Womens Health18(1) (2018) 1–8; https://doi.org/10.1186/s12905-018-0522-3Search in Google Scholar
B. Pistilli, A. Paci, A. R. Ferreira, A. Di Meglio, V. Poinsignon, A. Bardet, G. Menvielle, A. Dumas, S. Pinto, S. Dauchy, L. Fasse, P. H. Cottu, F. Lerebours, C. Coutant, A. Lesur, O. Tredan, P. Soulie, L. Vanlemmens, C. Jouannaud, C. Levy, S. Everhard, P. Arveux, A. L. Martin, A. Dima, N. U. Lin, A. H. Partridge, S. Delaloge, S. Michiels, F. André and I. Vaz-Luis, Serum detection of nonadherence to adjuvant tamoxifen and breast cancer recurrence risk, J. Clin. Oncol.38(24) (2020) 2762–2772; https://doi.org/10.1200/JCO.19.01758Search in Google Scholar
E. M. Quinn, C. Fleming and M. J. O’Sullivan, Endocrine therapy adherence : a cross-sectional study of factors affecting adherence and discontinuation of therapy, Ir. J. Med. Sci. 185(2) (2016) 383–392; https://doi.org/10.1007/s11845-015-1307-4Search in Google Scholar
V. Ziller, M. Kalder, U. S. Albert, W. Holzhauer, M. Ziller, U. Wagner and P. Hadji, Adherence to adjuvant endocrine therapy in postmenopausal women with breast cancer, Ann. Oncol.20(3) (2009) 431–436; https://doi.org/10.1093/annonc/mdn646Search in Google Scholar
L. R. Ayres, O. Baldoni Ade, A. P. Borges and L. R. Pereira, Adherence and discontinuation of oral hormonal therapy in patients with hormone receptor positive breast cancer, Int. J. Clin. Pharm. 36(1) (2014) 45–54; https://doi.org/10.1007/s11096-013-9833-5Search in Google Scholar
R. Font, J. A. Espinas, A. Barnadas, A. Izquierdo, J. Galceran, F. Saladie, R. Marcos-Gragera, A. Torrent, P. Manchon-Walsh and J. M. Borras, Influence of adherence to adjuvant endocrine therapy on disease-free and overall survival: a population-based study in Catalonia, Spain, Breast Cancer Res. Treat. 175(3) (2019) 733–740; https://doi.org/10.1007/s10549-019-05201-3Search in Google Scholar
D. L. Hershman, L. H. Kushi, T. Shao, D. Buono, A. Kershenbaum, W. Y. Tsai, L. Fehrenbacher, S. Lin Gomez, S. Miles and A. I. Neugut, Early discontinuation and nonadherence to adjuvant hormonal therapy in a cohort of 8,769 early-stage breast cancer patients, J. Clin. Oncol.28(27) (2010) 4120–4128; https://doi.org/10.1200/JCO.2009.25.9655Search in Google Scholar
S. McGuinness, L. Hughes, R. Moss-Morris, M. Hunter, S. Norton and Z. Moon, Adherence to adjuvant endocrine therapy among White British and ethnic minority breast cancer survivors in the United Kingdom, Eur. J. Cancer Care31(6) (2022) Article ID 13722 (11 pages); https://doi.org/10.1111/ecc.13722Search in Google Scholar
Z. Moon, R. Moss-Morris, M. S. Hunter, S. Carlisle and L. D. Hughes, Barriers and facilitators of adjuvant hormone therapy adherence and persistence in women with breast cancer: A systematic review, Patient Prefer. Adher.11 (2017) 305–322; https://doi.org/10.2147/PPA.S126651Search in Google Scholar
C. C. Murphy, L. K. Bartholomew, M. Y. Carpentier, S. M. Bluethmann and S. W. Vernon, Adherence to adjuvant hormonal therapy among breast cancer survivors in clinical practice: A systematic review, Breast Cancer Res. Treat. 134(2) (2012) 459–478; https://doi.org/10.1007/s10549-012-2114-5Search in Google Scholar
I. Yussof, N. A. Mohd Tahir, E. Hatah and N. Mohamed Shah, Factors influencing five-year adherence to adjuvant endocrine therapy in breast cancer patients: A systematic review, Breast62 (2022) 22–35; https://doi.org/10.1016/j.breast.2022.01.012Search in Google Scholar
M. P. van Herk-Sukel, L. V. Van De Poll-Franse, A. C. Voogd, G. A. P. Nieuwenhuijzen, J. W. W. Coebergh and R. M. C. Herings, Half of breast cancer patients discontinue tamoxifen and any endocrine treatment before the end of the recommended treatment period of 5 years: A population-based analysis, Breast Cancer Res. Treat. 122(3) (2010) 843–851; https://doi.org/10.1007/s10549-009-0724-3Search in Google Scholar
D. M. Waterhouse, K. A. Calzone, C. Mele and D. E. Brenner, Adherence to oral tamoxifen: A comparison of patient self-report, pill counts, and microelectronic monitoring, J. Clin. Oncol. 11(6) (1993) 1189–1197; https://doi.org/10.1200/JCO.1993.11.6.1189Search in Google Scholar
C. Lin, R. Clark, P. Tu, H. B. Bosworth and L. L. Zullig, Breast cancer oral anti-cancer medication adherence: a systematic review of psychosocial motivators and barriers, Breast Cancer Res. Treat. 165(2) (2017) 247–260; https://doi.org/10.1007/s10549-017-4317-2Search in Google Scholar
M. A. Franzoi, E. Agostinetto, M. Perachino, L. del Mastro, E. de Azambuja, I. Vaz-Luis, A. H. Partridge and M. Lambertini, Evidence-based approaches for the management of side-effects of adjuvant endocrine therapy in patients with breast cancer, Lancet Oncol.22(7) (2021) e303-e313; https://doi.org/10.1016/S1470-2045(20)30666-5Search in Google Scholar
L. K. Lambert, L. G. Balneaves, A. F. Howard and C. C. Gotay, Patient – reported factors associated with adherence to adjuvant endocrine therapy after breast cancer: an integrative review, Breast Cancer Res. Treat. 167(3) (2017) 615–633; https://doi.org//10.1007/s10549-017-4561-5Search in Google Scholar
S. Sawesi, J. S. Carpenter and J. Jones, Reasons for nonadherence to tamoxifen and aromatase inhibitors for the treatment of breast cancer: A literature review, Clin. J. Oncol. Nurs.18(3) (2014) 50–57; https://doi.org/10.1188/14.CJON.E50-E57Search in Google Scholar
K. L. Smith, N. Verma, A. L. Blackford, J. Lehman, K. Westbrook, D. Lim, J. Fetting, A. C. Wolff, D. Jelovac, R. S. Miller, R. Connolly, D. K. Armstrong, R. Nunes, K. Visvanathan, C. Riley, K. Papathakis, N. Zafman, J. Y. Sheng, C. Snyder and V. Stearns, Association of treatment-emergent symptoms identified by patient-reported outcomes with adjuvant endocrine therapy discontinuation, NPJ Breast Cancer8(1) (2022) Article ID 53 (13 pages); https://doi.org/10.1038/s41523-022-00414-0Search in Google Scholar
W. Wulaningsih, H. Garmo, J. Ahlgren, L. Holmberg, Y. Folkvaljon, A. Wigertz, M. Van Hemelrijck and M. Lambe, Determinants of non-adherence to adjuvant endocrine treatment in women with breast cancer: the role of comorbidity, Breast Cancer Res. Treat.172(1) (2018) 167–177; https://doi.org/10.1007/s10549-018-4890-zSearch in Google Scholar
J. Brett, N. J. Hulbert-Williams, D. Fenlon, M. Boulton, F. M. Walter, P. Donnelly, B. Lavery, A. Morgan, C. Morris, R. Horne and E. Watson, Psychometric properties of the Beliefs about Medicine Questionnaire-adjuvant endocrine therapy (BMQ-AET) for women taking AETs following early-stage breast cancer, Health Psychol. Open4(2) (2017); https://doi.org/10.1177/2055102917740469Search in Google Scholar
J. Brett, D. Fenlon, M. Boulton, N. J. Hulbert-Williams, F. M. Walter, P. Donnelly, B. Lavery, A. Morgan, C. Morris and E. Watson, Factors associated with intentional and unintentional non-adherence to adjuvant endocrine therapy following breast cancer, Eur. J. Cancer Care27(1) (2018) 1–9; https://doi.org/10.1111/ecc.12601Search in Google Scholar
H. Foot, A. La Caze, G. Gujral and N. Cottrell, The necessity-concerns framework predicts adherence to medication in multiple illness conditions: A meta-analysis, Patient Educ. Couns. 99(5) (2016) 706–717; https://doi.org/10.1016/j.pec.2015.11.004Search in Google Scholar
R. Horne, J. Weinman and M. Hankins, The beliefs about medicines questionnaire: The development and evaluation of a new method for assessing the cognitive representation of medication, Psychol. Health14 (1999) 1–24; https://doi.org/10.1080/08870449908407311Search in Google Scholar
R. Horne, S. C. E. Chapman, R. Parham, N. Freemantle, A. Forbes and V. Cooper, Understanding patients’ adherence-related beliefs about medicines prescribed for long-term conditions: A meta-analytic review of the Necessity-Concerns Framework, PLoS One8(12) e80633 (24 pages); https://doi.org/10.1371/journal.pone.0080633Search in Google Scholar
R. Horne and J. Weinman, Patients’ beliefs about prescribed medicines and their role in adherence to treatment in chronic physical illness, J. Psychosom. Res.47(6) (1999) 555–567; https://doi.org/10.1016/s0022-3999(99)00057-4Search in Google Scholar
C. T. Toivonen, T. M. Williamson, L. E. Carlson and L. M. Walker, Potentially modifiable factors associated with adherence to adjuvant endocrine therapy among breast cancer survivors: A systematic review, Cancers (Basel)13(1) (2020) Article ID 107 (22 pages); https://doi.org/10.3390/cancers13010107Search in Google Scholar
A. H. Y. Chan, R. Horne, M. Hankins and C. Chisari, The medication adherence report scale: A measurement tool for eliciting patients’ reports of nonadherence, Br. J. Clin. Pharmacol.86(7) (2020) 1281–1288; https://doi.org/10.1111/bcp.14193Search in Google Scholar
S. T. de Vries, J. C. Keers, R. Visser, D. de Zeeuw, F. M. Haaijer-Ruskamp, J. Voorham and P. Denig, Medication beliefs, treatment complexity, and non-adherence to different drug classes in patients with type 2 diabetes, J. Psychosom. Res.76(2) (2014) 134–138; https://doi.org/10.1016/j.jpsy-chores.2013.11.003Search in Google Scholar
Z. Moon, R. Moss-Morris, M. S. Hunter and L. D. Hughes, More than just side-effects: The role of clinical and psychosocial factors in non-adherence to tamoxifen, Br. J. Health Psychol.22(4) (2017) 998–1018; https://doi.org/10.1111/bjhp.12274Search in Google Scholar
J. Charan and T. Biswas, How to calculate sample size for different study designs in medical research?, Indian J. Psychol. Med.35(2) (2013) 121–126; https://doi.org/10.4103/0253-7176.116232Search in Google Scholar
E. A. Grunfeld, M. S. Hunter, P. Sikka and S. Mittal, Adherence beliefs among breast cancer patients taking tamoxifen, Patient Educ. Couns59(1) (2005) 97–102; https://doi.org/10.1016/j.pec.2004.10.005Search in Google Scholar
Y. Sheng and Z. Sheng, Is coefficient alpha robust to non-normal data?, Front Psychol. 3 (2012) Article ID 34 (13 pages); https://doi.org/10.3389/fpsyg.2012.00034Search in Google Scholar
T. M. Salgado, E. J. Davis, K. B. Farris, S. Fawaz, P. Batra and N. L. Henry, Identifying socio-demographic and clinical characteristics associated with medication beliefs about aromatase inhibitors among postmenopausal women with breast cancer, Breast Cancer Res. Treat.163(2) (2017) 311–319; https://doi.org/10.1007/s10549-017-4177-9Search in Google Scholar
A. L. Sutton, T. M. Salgado, J. He, A. Hurtado-de-Mendoza and V. B. Sheppard, Sociodemographic, clinical, psychosocial, and healthcare-related factors associated with beliefs about adjuvant endocrine therapy among breast cancer survivors, Support. Care in Cancer28(9) (2020) 4147–4154; https://doi.org/10.1007/s00520-019-05247-5Search in Google Scholar
K. C. Kadakia, K. M. Kidwell, D. L. Barton, A. F. Schott, D. F. Hayes, J. J. Griggs and N. L. Henry, Factors influencing the use of extended adjuvant endocrine therapy, Breast Cancer Res. Treat.175(1) (2019) 181–189; https://doi.org/10.1007/s10549-019-05145-8Search in Google Scholar
E. E. Bright, K. J. Petrie, A. H. Partridge and A. L. Stanton, Barriers to and facilitative processes of endocrine therapy adherence among women with breast cancer, Breast Cancer Res. Treat.158(2) (2016) 243–251; https://doi.org/10.1007/s10549-016-3871-3Search in Google Scholar
A. L. Stanton, K. J. Petrie and A. H. Partridge, Contributors to nonadherence and nonpersistence with endocrine therapy in breast cancer survivors recruited from an online research registry, Breast Cancer Res. Treat.145(2) (2014) 525–534; https://doi.org/10.1007/s10549-014-2961-3Search in Google Scholar
R. J. Thorneloe, L. H. Hall, F. M. Walter, L. Side, K. E. Lloyd and S. G. Smith, Knowledge of potential harms and benefits of tamoxifen among women considering breast cancer preventive therapy, Cancer Prev. Res.13(4) (2020) 411–421; https://doi.org/10.1158/1940-6207.CAPR-19-0424Search in Google Scholar
Y. Kim, Y. H. Min and S. B. Lee, Beliefs and attitudes toward endocrine therapy in patients with hormone receptor-positive breast cancer, Health Care Women Int. 42(7-9) (2021) 1086–1097; https://doi.org/10.1080/07399332.2020.1802460Search in Google Scholar
L. B. Wenzel, D. L. Fairclough, M. J. Brady, D. Cella, K. M. Garrett, B. C. Kluhsman, L. A. Crane and A. C. Marcus, Age-related differences in the quality of life of breast carcinoma patients after treatment, Cancer86(9) (1999) 1768–1774; https://doi.org/10.1002/(SICI)1097-0142(19991101)86:9<1768Search in Google Scholar
R. Condorelli and I. Vaz-Luis, Managing side effects in adjuvant endocrine therapy for breast cancer, Expert Rev. Anticancer Ther. 18(11) (2018) 1101–1112; https://doi.org/10.1080/14737140.2018.1520096Search in Google Scholar
T. Sella, P. D. Poorvu, K. J. Ruddy, S. I. Gelber, R. M. Tamimi, J. M. Peppercorn, L. Schapira, V. F. Borges, S. E. Come, A. H. Partridge and S. M. Rosenberg, Impact of fertility concerns on endocrine therapy decisions in young breast cancer survivors, Cancer127(16) (2021) 2888–2894; https://doi.org/10.1002/cncr.33596Search in Google Scholar
C. Castillo and N. Camejo, Impact of breast cancer treatments on fertility and the importance of timing for a fertility preservation intervention, Revista de Senologia y Patologia Mamaria34(4) (2022) 305–311; https://doi.org/10.1016/j.senol.2021.08.004Search in Google Scholar
J. Howard-Anderson, P. A. Ganz, J. E. Bower and A. L. Stanton, Quality of life, fertility concerns, and behavioral health outcomes in younger breast cancer survivors: A systematic review, J. Natl. Cancer Inst. 104(5) (2012) 386–405; https://doi.org/10.1093/jnci/djr541Search in Google Scholar
A. Philipovskiy, A. Campbell, R. Heydarian, B. Castillo, A. K. Dwivedi, R. McCallum, R. Aguilera, S. Gaur and Z. Nahleh, Adherence to adjuvant aromatase inhibitor therapy among postmenopausal hispanic/latino women with breast cancer, Anticancer Res.40(2) (2020) 857–864; https://doi.org/10.21873/anticanres.14018Search in Google Scholar
E. Ekinci, S. Nathoo, T. Korattyil, A. Vadhariya, H. A. Zaghloul, P. A. Niravath, S. M. Abughosh and M. V. Trivedi, Interventions to improve endocrine therapy adherence in breast cancer survivors: what is the evidence?, J. Cancer Survivorship12(3) (2018) 348–356; https://doi.org/10.1007/s11764-017-0674-4Search in Google Scholar
V. Ziller, I. Kyvernitakis, D. Knöll, A. Storch, O. Hars and P. Hadji, Influence of a patient information program on adherence and persistence with an aromatase inhibitor in breast cancer treatment - the COMPAS study, BMC Cancer13 (2013) Article ID 407 (9 pages); https://doi.org/10.1186/1471-2407-13-407Search in Google Scholar
C. Markopoulos, P. Neven, M. Tanner, M. Marty, R. Kreienberg, L. Atkins, A. Franquet, M. Gnant, S. Neciosup, P. Tesarova, S. Barni and V. Deschamp, Does patient education work in breast cancer? Final results from the global CARIATIDE study, Future Oncol.11(2) (2015) 205–217; https://doi.org/10.2217/fon.14.179Search in Google Scholar
V. L. Wagner, W. Jing, F. P. Boscoe, M. J. Schymura, P. J. Roohan and F. C. Gesten, Improving adjuvant hormone therapy use in medicaid managed care-insured women, New York State, 2012–2014, Prev. Chronic Dis.13 (2016) 1–9; https://doi.org/10.5888/pcd13.160185Search in Google Scholar
K. D. Yu, Y. Zhou, G. Y. Liu, B. Li, P. Q. He, H. W. Zhang, L. H. Lou, X. J. Wang, S. Wang, J. H. Tang, Y. H. Liu, X. Wang, Z. F. Jiang, L. W. Ma, L. Gu, M. Z. Cao, Q. Y. Zhang, S. M. Wang, F. X. Su, H. Zheng, H. Y. Li, L. L. Tang, S. R. Sun, J. P. Liu, Z. M. Shao and Z. Z. Shen, A prospective, multicenter, controlled, observational study to evaluate the efficacy of a patient support program in improving patients’ persistence to adjuvant aromatase inhibitor medication for postmenopausal, early stage breast cancer, Breast Cancer Res. Treat.134(1) (2012) 307–313; https://doi.org/10.1007/s10549-012-2059-8Search in Google Scholar
P. Hadji, M. Blettner, N. Harbeck, C. Jackisch, H. J. Lück, C. Windemuth-Kieselbach, S. Zaun and R. Kreienberg, The patient’s anastrozole compliance to therapy (PACT) program: A randomized, in-practice study on the impact of a standardized information program on persistence and compliance to adjuvant endocrine therapy in postmenopausal women with early breast cance, Ann. Oncol.24(6) (2013) 1505–1512; https://doi.org/10.1093/annonc/mds653Search in Google Scholar
A. S. Oberguggenberger, M. Sztankay, B. Beer, B. Schubert, V. Meraner, H. Oberacher, G. Kemmler, J. Giesinger, E. Gamper, B. Sperner-Unterweger, C. Marth, B. Holzner and M. Hubalek, Adherence evaluation of endocrine treatment in breast cancer: Methodological aspects, BMC Cancer 12 (2012) Article ID 474 (9 pages); https://doi.org/10.1186/1471-2407-12-474Search in Google Scholar
M. J. Stirratt, J. Dunbar-Jacob, H. M. Crane, J. M. Simoni, S. Czajkowski, M. E. Hilliard, J. E. Aikens, C. M. Hunter, D. I. Velligan, K. Huntley, G. Ogedegbe, C. S. Rand, E. Schron and W. J. Nilsen, Self-report measures of medication adherence behavior: recommendations on optimal use, Transl. Behav. Med. 5(4) (2015) 470–482; https://doi.org/10.1007/s13142-015-0315-2Search in Google Scholar